SK18012001A3 - Použitie 5,6-dihydroxy-2-metylaminotetralínu alebo 5,6-diizobutyroyloxy-2-metylaminotetralínu - Google Patents
Použitie 5,6-dihydroxy-2-metylaminotetralínu alebo 5,6-diizobutyroyloxy-2-metylaminotetralínu Download PDFInfo
- Publication number
- SK18012001A3 SK18012001A3 SK1801-2001A SK18012001A SK18012001A3 SK 18012001 A3 SK18012001 A3 SK 18012001A3 SK 18012001 A SK18012001 A SK 18012001A SK 18012001 A3 SK18012001 A3 SK 18012001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- chf
- methylaminotetralin
- dihydroxy
- left ventricular
- dopamine
- Prior art date
Links
- BHDFPNRSDABMPW-UHFFFAOYSA-N 6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol Chemical compound C1=CC(O)=C(O)C2=C1CC(NC)CC2 BHDFPNRSDABMPW-UHFFFAOYSA-N 0.000 title claims abstract description 9
- OMMYLOLVPCCZQZ-UHFFFAOYSA-N [6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate Chemical compound C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1CC(NC)CC2 OMMYLOLVPCCZQZ-UHFFFAOYSA-N 0.000 title description 5
- 239000005541 ACE inhibitor Substances 0.000 claims abstract description 7
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims abstract description 7
- 208000033774 Ventricular Remodeling Diseases 0.000 claims abstract description 7
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract description 7
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims abstract description 5
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- WZEWXAXWUPNHSB-UHFFFAOYSA-N [5-amino-6-methyl-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate Chemical compound NC1C(C)CCC2=C(OC(=O)C(C)C)C(OC(=O)C(C)C)=CC=C21 WZEWXAXWUPNHSB-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 16
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical group C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 claims description 9
- 229960005227 delapril Drugs 0.000 claims description 9
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 238000007634 remodeling Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 3
- TWTMQRXNAZGSCE-UHFFFAOYSA-N hydron;[6-(methylamino)-1-(2-methylpropanoyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl] 2-methylpropanoate;chloride Chemical compound Cl.C1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C2=C1CC(NC)CC2 TWTMQRXNAZGSCE-UHFFFAOYSA-N 0.000 description 34
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 30
- MIMDMPWWTWVHFK-UHFFFAOYSA-N 6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol;hydrochloride Chemical compound Cl.C1=CC(O)=C(O)C2=C1CC(NC)CC2 MIMDMPWWTWVHFK-UHFFFAOYSA-N 0.000 description 27
- 230000000694 effects Effects 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 20
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 229960003638 dopamine Drugs 0.000 description 14
- 206010019280 Heart failures Diseases 0.000 description 13
- 206010007559 Cardiac failure congestive Diseases 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 230000000004 hemodynamic effect Effects 0.000 description 10
- 230000002093 peripheral effect Effects 0.000 description 10
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 9
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 9
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 9
- 230000003291 dopaminomimetic effect Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000002182 neurohumoral effect Effects 0.000 description 7
- 229960002748 norepinephrine Drugs 0.000 description 7
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 7
- 230000002861 ventricular Effects 0.000 description 7
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000002934 diuretic Substances 0.000 description 6
- 229940030606 diuretics Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000011360 adjunctive therapy Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical class C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000020446 Cardiac disease Diseases 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 4
- 206010037368 Pulmonary congestion Diseases 0.000 description 4
- 150000003943 catecholamines Chemical class 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 230000001077 hypotensive effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000003518 presynaptic effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 108060003345 Adrenergic Receptor Proteins 0.000 description 3
- 102000017910 Adrenergic receptor Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001800 adrenalinergic effect Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 208000027744 congestion Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 208000021822 hypotensive Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 230000036581 peripheral resistance Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000002889 sympathetic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000000304 vasodilatating effect Effects 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000208011 Digitalis Species 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 2
- 229960001253 domperidone Drugs 0.000 description 2
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 230000036513 peripheral conductance Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- WVTXFXCXXUAZLK-UHFFFAOYSA-N 6-(methylamino)-5,6,7,8-tetrahydronaphthalene-1,2-diol;hydrobromide Chemical group [Br-].C1=CC(O)=C(O)C2=C1CC([NH2+]C)CC2 WVTXFXCXXUAZLK-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229940123415 Beta 2 adrenoreceptor antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000004141 dimensional analysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000035874 hyperreactivity Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 229960004145 levosulpiride Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 230000008700 sympathetic activation Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/328,434 US6103760A (en) | 1995-03-17 | 1999-06-09 | Aminotetralin derivative for the therapy of cardiovascular diseases |
| PCT/EP2000/005231 WO2000076544A1 (en) | 1996-03-13 | 2000-06-07 | Aminotetralin derivative for the therapy of cardiovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK18012001A3 true SK18012001A3 (sk) | 2002-04-04 |
Family
ID=23280968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1801-2001A SK18012001A3 (sk) | 1999-06-09 | 2000-06-07 | Použitie 5,6-dihydroxy-2-metylaminotetralínu alebo 5,6-diizobutyroyloxy-2-metylaminotetralínu |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6576671B1 (pt) |
| EP (1) | EP1183046B1 (pt) |
| JP (1) | JP2003501483A (pt) |
| KR (1) | KR20020005772A (pt) |
| CN (1) | CN1354676A (pt) |
| AT (1) | ATE248607T1 (pt) |
| AU (1) | AU766230B2 (pt) |
| BR (1) | BR0012121A (pt) |
| CA (1) | CA2376715A1 (pt) |
| CZ (1) | CZ20014406A3 (pt) |
| DE (1) | DE60004996T2 (pt) |
| DK (1) | DK1183046T3 (pt) |
| EA (1) | EA003830B1 (pt) |
| EE (1) | EE200100663A (pt) |
| ES (1) | ES2206240T3 (pt) |
| HK (1) | HK1044279B (pt) |
| HU (1) | HUP0201650A2 (pt) |
| IL (1) | IL146962A0 (pt) |
| MA (1) | MA26796A1 (pt) |
| MX (1) | MXPA01012638A (pt) |
| NO (1) | NO20016000L (pt) |
| NZ (1) | NZ515727A (pt) |
| PL (1) | PL352119A1 (pt) |
| PT (1) | PT1183046E (pt) |
| SK (1) | SK18012001A3 (pt) |
| TR (1) | TR200103526T2 (pt) |
| ZA (1) | ZA200110091B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10053397A1 (de) | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| US20050101668A1 (en) * | 2003-07-24 | 2005-05-12 | Chiesi Farmaceutici S.P.A. | Aminotetralin derivatives as a medicament for the treatment and prevention of myocardial ischemic conditions |
| EP1500392A1 (en) * | 2003-07-24 | 2005-01-26 | CHIESI FARMACEUTICI S.p.A. | Aminotetralin derivatives as a medicament for the treatment and prevention of myocardial ischemic conditions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4134997A (en) * | 1977-03-01 | 1979-01-16 | University Of Iowa Research Foundation | Effect of an aminotetralin derivative on coronary blood flow in infarcted hearts |
| IT1275935B1 (it) * | 1995-03-17 | 1997-10-24 | Chiesi Farma Spa | Derivato di aminotetralina per la terapia di malattie cardiovascolari |
-
2000
- 2000-06-07 AT AT00935184T patent/ATE248607T1/de not_active IP Right Cessation
- 2000-06-07 JP JP2001502876A patent/JP2003501483A/ja active Pending
- 2000-06-07 KR KR1020017015440A patent/KR20020005772A/ko not_active Application Discontinuation
- 2000-06-07 EP EP00935184A patent/EP1183046B1/en not_active Expired - Lifetime
- 2000-06-07 PL PL00352119A patent/PL352119A1/xx not_active Application Discontinuation
- 2000-06-07 DE DE60004996T patent/DE60004996T2/de not_active Expired - Fee Related
- 2000-06-07 DK DK00935184T patent/DK1183046T3/da active
- 2000-06-07 CN CN00808624A patent/CN1354676A/zh active Pending
- 2000-06-07 AU AU50765/00A patent/AU766230B2/en not_active Ceased
- 2000-06-07 EA EA200101159A patent/EA003830B1/ru not_active IP Right Cessation
- 2000-06-07 US US10/009,352 patent/US6576671B1/en not_active Expired - Fee Related
- 2000-06-07 NZ NZ515727A patent/NZ515727A/xx unknown
- 2000-06-07 CA CA002376715A patent/CA2376715A1/en not_active Abandoned
- 2000-06-07 TR TR2001/03526T patent/TR200103526T2/xx unknown
- 2000-06-07 EE EEP200100663A patent/EE200100663A/xx unknown
- 2000-06-07 PT PT00935184T patent/PT1183046E/pt unknown
- 2000-06-07 BR BR0012121-5A patent/BR0012121A/pt not_active IP Right Cessation
- 2000-06-07 IL IL14696200A patent/IL146962A0/xx unknown
- 2000-06-07 ES ES00935184T patent/ES2206240T3/es not_active Expired - Lifetime
- 2000-06-07 SK SK1801-2001A patent/SK18012001A3/sk unknown
- 2000-06-07 MX MXPA01012638A patent/MXPA01012638A/es not_active Application Discontinuation
- 2000-06-07 HU HU0201650A patent/HUP0201650A2/hu unknown
- 2000-06-07 CZ CZ20014406A patent/CZ20014406A3/cs unknown
-
2001
- 2001-12-06 MA MA26435A patent/MA26796A1/fr unknown
- 2001-12-07 ZA ZA200110091A patent/ZA200110091B/xx unknown
- 2001-12-07 NO NO20016000A patent/NO20016000L/no not_active Application Discontinuation
-
2002
- 2002-08-06 HK HK02105724.0A patent/HK1044279B/zh not_active IP Right Cessation
-
2003
- 2003-04-11 US US10/411,313 patent/US20030207944A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL352119A1 (en) | 2003-07-28 |
| CZ20014406A3 (cs) | 2002-04-17 |
| ZA200110091B (en) | 2002-12-09 |
| EP1183046B1 (en) | 2003-09-03 |
| TR200103526T2 (tr) | 2002-04-22 |
| MXPA01012638A (es) | 2002-07-22 |
| JP2003501483A (ja) | 2003-01-14 |
| NO20016000L (no) | 2002-02-11 |
| DE60004996T2 (de) | 2004-07-22 |
| CN1354676A (zh) | 2002-06-19 |
| KR20020005772A (ko) | 2002-01-17 |
| NO20016000D0 (no) | 2001-12-07 |
| DE60004996D1 (de) | 2003-10-09 |
| EA003830B1 (ru) | 2003-10-30 |
| NZ515727A (en) | 2003-06-30 |
| BR0012121A (pt) | 2002-05-14 |
| PT1183046E (pt) | 2003-12-31 |
| HK1044279A1 (en) | 2002-10-18 |
| HUP0201650A2 (hu) | 2002-12-28 |
| EP1183046A1 (en) | 2002-03-06 |
| IL146962A0 (en) | 2002-08-14 |
| MA26796A1 (fr) | 2004-12-20 |
| ES2206240T3 (es) | 2004-05-16 |
| EE200100663A (et) | 2003-04-15 |
| ATE248607T1 (de) | 2003-09-15 |
| CA2376715A1 (en) | 2000-12-21 |
| AU5076500A (en) | 2001-01-02 |
| EA200101159A1 (ru) | 2002-06-27 |
| AU766230B2 (en) | 2003-10-09 |
| DK1183046T3 (da) | 2004-01-05 |
| HK1044279B (zh) | 2004-01-16 |
| US6576671B1 (en) | 2003-06-10 |
| US20030207944A1 (en) | 2003-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200323771A1 (en) | Methods for Administration and Methods for Treating Cardiovascular Diseases with Resiniferatoxin | |
| US6103760A (en) | Aminotetralin derivative for the therapy of cardiovascular diseases | |
| CA2739463C (en) | Methods and compositions for treatment of acute heart failure | |
| SK18012001A3 (sk) | Použitie 5,6-dihydroxy-2-metylaminotetralínu alebo 5,6-diizobutyroyloxy-2-metylaminotetralínu | |
| WO2000076544A1 (en) | Aminotetralin derivative for the therapy of cardiovascular diseases | |
| EP1331004A2 (en) | Aminotetralin Derivative for the Therapy of Cardiovascular Diseases | |
| JP6935930B2 (ja) | 生薬成分を含む肺高血圧症の予防又は治療剤 | |
| Atakhanova et al. | DRY COUGH AS AN ADVERSE DRUG REACTION DURING THE USE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS |